Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BP1001 + decitabine
- Development stage
- Unknown
- Lead developer
- Bio-Path Holdings
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
BP1001 + decitabine is an investigational combination therapy for acute myeloid leukemia (AML). BP1001 (prexigebersen) is a liposome-incorporated antisense oligonucleotide targeting growth factor receptor bound protein-2 (Grb2), a key adaptor protein in oncogenic tyrosine kinase signaling pathways that drive AML progression. Decitabine is a hypomethylating agent and pyrimidine nucleoside analogue that inhibits DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes. The combination aims to enhance the sensitivity of AML cells to chemotherapy by disrupting Grb2-mediated signaling while simultaneously altering gene expression through epigenetic modulation. This regimen is being studied primarily in patients with newly diagnosed or relapsed/refractory AML who are unsuitable for intensive chemotherapy[3][7][9].
- Brand names
- Dacogen
- Other names
- prexigebersen + decitabineBP1001 + decitabine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)Growth factor receptor-bound protein 2 mRNA (GRB2 mRNA)
Beyond the preview
Go deeper on BP1001 + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BP1001 + decitabine.